Potential Parkinson’s Vaccine, Affitope PD01A, Safe and Possibly Effective in Long-term, Phase 1 Trial Series Finds

[Farooqji]

Affitope PD01A is an experimental vaccine — a synthetic aSyn-mimicking peptide based on Affiris’ Affitome technology — that targets alpha-synuclein by inducing an immune response that generates antibodies specifically against it.

As such, Affitope PD01A has the potential to modify disease progression.

parkinsonsnewstoday.com/201...

[Kia17]

Thanks for sharing

[Hikoi]

Thanks for this.

newscientist.com/article/mg...

An earlier press release. Good to see it progressing even though its at about the speed of continental drift

[jeffreyn]

The recent update from AFFiRiS has triggered a substantial post on the SoPD blog:

scienceofparkinsons.com/201...